INSM (Insmed) Ending Cash Position: $545 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

INSM Insmed Inc INSM
68 GF Score
Price $128.46
GF Value $199.02
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Insmed Ending Cash Position?

Insmed INSM +0.11% 68 Ending Cash Position is $545 Mil as of Jun. 2026. GuruFocus rates INSM with a GF Score™ of 68/100 and a GF Value™ of $199.02 (Possible Value Trap). The stock has 4 warning signs investors should review.

Insmed's Ending Cash Position for the quarter that ended in Jun. 2026 was $545 Mil.

Insmed's quarterly Ending Cash Position increased from Dec. 2025 ($510 Mil) to Mar. 2026 ($582 Mil) but then declined from Mar. 2026 ($582 Mil) to Jun. 2026 ($545 Mil).

Insmed's annual Ending Cash Position increased from Dec. 2023 ($482 Mil) to Dec. 2024 ($555 Mil) but then declined from Dec. 2024 ($555 Mil) to Dec. 2025 ($510 Mil).

Insmed Ending Cash Position Related Terms

Insmed Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Insmed's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Insmed Ending Cash Position Chart

Insmed Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 716.78 1,074.04 482.37 555.03 510.45

Insmed Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,284.32 334.76 510.45 582.19 544.77
INSM
68GF Score
Insmed Inc INSM
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Insmed Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Insmed's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=555.03+-44.585
=510

Insmed's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=582.188+-37.423
=545

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $545 Mil mean?
Insmed (INSM) has a Ending Cash Position of $545 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Insmed and its competitors.
Is Insmed's Ending Cash Position too high?
Insmed's current Ending Cash Position is $545 Mil. Overall, Insmed has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Insmed's Ending Cash Position compare to INCY and BNTX?
Insmed's Ending Cash Position of $545 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Insmed and its competitors. Insmed's current Ending Cash Position is $545 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insmed stock overvalued right now?
Based on GuruFocus' analysis, Insmed (INSM) is currently considered Possible Value Trap. The stock's GF Value™ is $199.02, compared to a current price of $128.46 — trading 35.5% below its estimated fair value. The current Ending Cash Position is $545 Mil. Insmed's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Insmed (INSM), the current Ending Cash Position is $545 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Insmed (INSM) Overvalued in 2026?

Based on GuruFocus' analysis, Insmed stock appears to be undervalued. The current stock price of $128.46 is trading 35.5% below its estimated GF Value™ of $199.02. GuruFocus considers Insmed to be Possible Value Trap.

Key valuation signals for INSM:

  • Ending Cash Position: $545 Mil
  • GF Value™: $199.02 vs. price of $128.46 (35.5% below fair value)
  • GF Score™: 68/100 with 4 warning signs

No single metric tells the full story. See the INSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Insmed Business Description

Address 700 US Highway 202/206, Bridgewater, NJ, USA, 08807
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
68GF Score

Get the complete analysis for INSM

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$128.46
Price
$199.02
GF Value